Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track ... Interest expense: Interest expense for the third quarter of 2025 was $11.0 million, compared to $11.4 million for the third ...
Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the third quarter ended September 30, 2025 and ...
Nearly 500 members of the Carnegie Mellon University community have signed a petition calling for an independent, externally led review of the university’s mental health policies and support ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback